EGFR and nasopharyngeal carcinoma: Some of our results, such as the EGFR signaling pathway‐erlotinib‐FOXQ1‐EGFR axis, is consistent with the previous studies showing that FOXQ1 promotes the development of angiogenic mimicry, which accelerates the spread of nasopharyngeal carcinoma, and that EGFR inhibitors can effectively suppress this process.35